The antitussive effect of dextromethorphan in relation to CYP2D6 activity

British Journal of Clinical Pharmacology

Volumn 48, Issue 3, 1999, Pages 382-387

  Abdul Manap, R ^a   Wright, C E ^a   Gregory, A ^a   Rostami Hodjegan, A ^a   Meller, S T ^b   Kelm, G R ^b   Lennard, M S ^a   Tucker, G T ^a   Morice, A H ^a,c  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b PROCTER AND GAMBLE COMPANY   (United States)

^c UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Antitussive effect; CYP2D6; Dextromethorphan; Genetic polymorphism

Indexed keywords

CITRIC ACID; CYTOCHROME P450; DEXTROMETHORPHAN; DEXTRORPHAN; QUINIDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG METABOLISM; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; ANTITUSSIVE AGENTS; COUGH; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP2D6; DEXTROMETHORPHAN; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; QUINIDINE; TREATMENT OUTCOME;

EID: 0032842655     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00029.x     Document Type: Article

References (25)

1. Cass LJ, Frederik WS. Evaluation of a new antitussive agent. N Engl J Med 1953; 249: 132-136.
2. Matthys H, Bleicher B, Bleicher U. Dextromethorphan and codeine: objective assessment of antitussive activity in patients with chronic cough. J Int Med Res 1983; 11: 92-100.
3. Cass LJ, Frederik WS. Quantitative comparison of cough suppressant effects of Romilar and other antitussive agents. J Lab Clin Med 1956; 48: 879-885.
4. Aylward M, Maddock J, Davies D, Protheroe D, Leideman T. Dextromethorphan and codeine: comparison of plasma kinetics and antitussive effects. Eur J Resp Dis 1984; 65: 283-291.
5. Parvez L, Vaidya M, Sakhardande A, Subburaj S, Rajagopalan TG. Evaluation of antitussive agents in man. Pulmon Pharmacol 1996; 9: 299-308.
6. Grattan TJ, Marshall AE, Higgins KS, Morice AH. The effect of inhaled and oral dextromethorphan on citric acid induced cough in man. Br J Clin Pharmacol 1995; 39: 261-263.
7. Kartunnen P, Tukiainen H, Silvasti M, Kolonen S. Antitussive effect of dextromethorphan and dextromethorphan-salbutamol combination in healthy volunteers with artificially induced cough. Respiration 1987; 52: 49-53.
8. Barnhart JW. The urinary excretion of dextromethorphan and three metabolites in dogs and humans. Toxicol Appl Pharmacol 1980; 55: 43-48.
9. Gorski JC, Jones DR, Wrighton SA, Hall SD. Characterisation of dextromethorphan N-demethylation by human liver microsomes-contribution of the cytochrome P450, 3A (CYP3A) subfamily. Biochem Pharmacol 1994 48: 173-182.
10. Von Moltke LL, Greenblatt DJ, Grassi JG, et al. Revaluation of the specificity of dextromethorphan as an index substrate. Clin Pharmacol Ther 1998; 63: 227.
11. Von Moltke LL, Greenblatt DJ, Grassi JG, et al. Multiple human chromosomes contribute to biotransformation of dextromethorphan in vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A. J Pharm Pharmacol 1998; 50: 997-1004.
12. Schmider J, Greenblatt DJ, Fogelman SM, Von Moltke LL, Shader RI. Metabolism of dextromethorphan in vitro: involvement of cytochromes P450 2D6 and 3A3/4, with a possible role of 2E1. Biopharm Drug Dispos 1997; 18: 227-240.
13. Jacq Aigran E, Funck-Brentano C, Cresteil T. CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics 1993; 3: 197-204.
14. Nielsen MD, Brosen K, Gram LF. A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man. Br J Clin Pharmacol 1990; 29: 299-304.
15. Brinn R, Brosen K, Gram LF, Haghfelt T, Otton SV. Sparteine oxidation is practically abolished in quinidine treated patients. Br J Clin Pharmacol 1986; 22: 194-197.
16. Zhang Y, Britto MR, Valderhaug KL, Wedlund PJ, Smith RA. Dextromethorphan: enhancing its systemic bioavailability by way of low-dose quinidine mediated inhibition of cytochome P4502D6. Clin Pharmacol Ther 1992; 51: 647-655.
17. Capon DA, Bochner F, Kerry N, Mikus C, Danz C, Somogyi AA. The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans. Clin Pharmacol Ther 1996; 60: 296-307.
18. Lennard MS, Silas JH, Smith AJ, Tucker GT. Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detection. J Chromatogr 1977; 133: 161-166.
19. Armitage P, Berry G. The planning of statistical investigations. In Statistical Methods In Medical Research, 2nd edn, Blackwell Scientific Publications, 1987: p. 182.
20. Chen ZR, Somogyi AA, Bochner F. Simultaneous determination of dextromethorphan and 3 metabolites in plasma and urine using high-performance liquid-chromatography with application to their disposition in man. Ther Drug Monit 1990; 12: 97-104.
21. Kohler D, Hartter S, Fuchs K, Siegarhart W, Hiemke C. CYP2D6 genotype and phenotyping by determination of dextromethorphan and metabolites in serum of healthy controls and of patients under psychotropic medication. Pharmacogenetics 1997; 7: 453-461.
22. Henthorn TK, Benitez J, Avram MJ, et al. Assessment of the debrisoquin and dextromethorphan phenotyping tests by Gaussian mixture distributions analysis. Clin Pharmacol Ther 1989; 45: 328-333.
23. Guttendorf RJ, Britto M, Blouin RA, Foster TS, John W, Pittman KA et al. Rapid screening for polymorphisms in dextromethorphan and mephenytoin metabolism. Br J Clin Pharmacol 1990; 29: 373-380.
24. Morice AH. Inhalation cough challenge in the investigation of the cough reflex and antitussives. Pulmon Pharmacol 1996; 9: 281-284.
25. Braga PC, Fossati A, Vimercati MG, Caputo R, Guffanti EE. Dextrorphan and dextromethorphan: comparative antitussive effects on guinea pigs. Drugs Exp Clin Res 1994; 20: 199-203.